1.03
4.02%
0.0398
After Hours:
1.04
0.01
+0.97%
Allarity Therapeutics Inc stock is traded at $1.03, with a volume of 618.19K.
It is up +4.02% in the last 24 hours and up +7.85% over the past month.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.
See More
Previous Close:
$0.9902
Open:
$1.02
24h Volume:
618.19K
Relative Volume:
0.58
Market Cap:
$4.57M
Revenue:
-
Net Income/Loss:
$-11.90M
P/E Ratio:
-0.005
EPS:
-206.0125
Net Cash Flow:
$-12.75M
1W Performance:
-3.74%
1M Performance:
+7.85%
6M Performance:
+406.39%
1Y Performance:
-89.38%
Allarity Therapeutics Inc Stock (ALLR) Company Profile
Name
Allarity Therapeutics Inc
Sector
Industry
Phone
401-426-4664
Address
24 SCHOOL ST., 2ND FLOOR, BOSTON
Compare ALLR with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
ALLR
Allarity Therapeutics Inc
|
1.03 | 4.57M | 0 | -11.90M | -12.75M | -206.01 |
VRTX
Vertex Pharmaceuticals Inc
|
416.96 | 107.38B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
693.23 | 76.18B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
659.81 | 39.45B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
249.16 | 32.14B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
112.76 | 27.03B | 3.30B | -501.07M | 1.03B | -2.1146 |
Allarity Therapeutics Inc Stock (ALLR) Latest News
2025-01-15 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Allarity Therapeutics, Inc. (ALLR) And Encourages Stockholders to Reach Out | NDAQ:ALLR | Press Release - Stockhouse Publishing
Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Stockholders to Connect - AccessWire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on B - GuruFocus.com
Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Allarity Therapeutics, Inc. (ALLR) and Encourages Stockholders to Learn More About the Investigation - AccessWire
2025-01-02 | Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:ALLR | Press Release - Stockhouse Publishing
Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
2024-12-30 | Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Investors to Inquire about Securities Investigation | NDAQ:ALLR | Press Release - Stockhouse Publishing
ALLR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Allarity Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - The Eastern Progress Online
ALLARITY THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Allarity Therapeutics, Inc. (NASDAQ: ALLR) for potential violations of federal securities laws - The Eastern Progress Online
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit - Kilgore News Herald
ALLR Deadline: ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit - The Eastern Progress Online
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - The Eastern Progress Online
Allarity Therapeutics stock hits 52-week low at $1.03 - Investing.com
Allarity Therapeutics stock hits 52-week low at $1.03 By Investing.com - Investing.com UK
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allarity Therapeutics, Inc. Inc. of Class Action Lawsuit and Upcoming DeadlinesALLR - Longview News-Journal
Allarity Therapeutics, Inc. Investors: Please contact the - GlobeNewswire
Allarity Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 12, 2024 Deadline to file Lead Plaintiff Motion - GlobeNewswire Inc.
Allarity Therapeutics stock hits 52-week low at $1.14 By Investing.com - Investing.com South Africa
Allarity Therapeutics stock hits 52-week low at $1.14 - Investing.com
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, I - GuruFocus.com
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates - GuruFocus.com
Allarity Therapeutics stock hits 52-week low at $1.25 By Investing.com - Investing.com Canada
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements - GlobeNewswire
Allarity's Phase 2 Cancer Drug Shows Promise: Patients Exceed 14-Month Treatment | ALLR Stock News - StockTitan
Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights - The Manila Times
Allarity Therapeutics Reports $18.5M Cash Position, Extended Runway in Q3 Results | ALLR Stock News - StockTitan
FINAL REMINDER ALLR DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Allarity Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit! - AccessWire
DEADLINE ALERT for ALLR, and COIN: The Law Offices of Frank - GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics - Business Wire
FINAL ALLR DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Allarity Therapeutics, Inc. Investors to Join the Class Action Lawsuit! - AccessWire
ALLR DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, - GlobeNewswire
ALLR DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. - The Bakersfield Californian
Allarity Therapeutics Inc Stock (ALLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):